0001225208-19-003444.txt : 20190222 0001225208-19-003444.hdr.sgml : 20190222 20190222181728 ACCESSION NUMBER: 0001225208-19-003444 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20190220 FILED AS OF DATE: 20190222 DATE AS OF CHANGE: 20190222 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pierce David A CENTRAL INDEX KEY: 0001529751 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-11083 FILM NUMBER: 19627621 MAIL ADDRESS: STREET 1: BOSTON SCIENTIFIC CORPORATION STREET 2: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: BOSTON SCIENTIFIC CORP CENTRAL INDEX KEY: 0000885725 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 042695240 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 BUSINESS PHONE: 508-683-4000 MAIL ADDRESS: STREET 1: 300 BOSTON SCIENTIFIC WAY CITY: MARLBOROUGH STATE: MA ZIP: 01752-1234 4 1 doc4.xml X0306 4 2019-02-20 0000885725 BOSTON SCIENTIFIC CORP BSX 0001529751 Pierce David A 300 BOSTON SCIENTIFIC WAY MARLBOROUGH MA 01752-1234 1 EVP,Pres MedSurg Common Stock 2019-02-20 4 A 0 26070.0000 0.0000 A 52223.0000 D Common Stock 2019-02-20 4 S 0 1952.0000 39.8600 D 50271.0000 D Common Stock 2019-02-20 4 F 0 11331.0000 40.1100 D 38940.0000 D Performance Share Units 2019-02-20 4 A 0 16318.0000 0.0000 A 2020-12-31 2020-12-31 Common Stock 16318.0000 16318.0000 D On February 22, 2016, the reporting person was awarded a target number of performance share units under the Company's 2016 Total Shareholder Return Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's total shareholder return performance percentile relative to that of the other companies in the S&P 500 Healthcare Index over the three annual performance cycles comprising the three-year period ended December 31, 2018 and subject to the completion of the concurrent three-year individual service period. On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined and the individual service period was satisfied. This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Each performance share unit represents the Company's commitment to issue one share of Boston Scientific common stock. On February 12, 2018, the reporting person was awarded a target number of performance share units under the Company's 2018 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person would be based on the Company's 2018 adjusted free cash flow measured against its 2018 financial plan over the one-year performance period ending December 31, 2018 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 20, 2019, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The performance share units so determined will vest in whole upon the completion of the individual service period that ends on December 31, 2020. /s/ Vance R. Brown, Attorney-in-fact 2019-02-22